12/15-lipoxygenases mediate toll-like receptor 4-dependent nociplastic pain hypersensitivity in female mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (mice)
PubMed 40667997 · doi:10.1097/j.pain.0000000000003711
What was done
Researchers investigated central Toll-like receptor 4 (TLR4)-dependent pain hypersensitivity in male and female C57BL/6N mice following intrathecal (IT) lipopolysaccharide (LPS) administration. They evaluated behavioral and functional outcomes, including tactile and cold allodynia, grip force deficits, and locomotor activity. Spinal release of 12/15-lipoxygenase (12/15-LOX) metabolites and 12/15-LOX enzyme expression were measured. The therapeutic effect of systemic 12/15-LOX inhibitors (ML355 targeting 12-LOX-p and ML351 targeting 15-LOX-1) was tested, as well as the capacity of 12/15-LOX metabolites administered spinally or peripherally to induce hyperalgesic priming.
What was found
The abstract reports directional outcomes without exact numerical values, sample sizes, or confidence intervals. Female C57BL/6N mice given IT LPS developed tactile allodynia, cold allodynia, grip force deficits, a modest increase in locomotor activity, and spinal release of 12/15-LOX metabolites. Systemic administration of ML355 or ML351 completely reversed allodynia and grip force deficits. Subthreshold spinal or intraplantar administration of 12/15-LOX metabolites induced tactile allodynia in a hyperalgesic priming model.
Why it matters
These findings suggest 12/15-LOX enzymes mediate TLR4-driven pain hypersensitivity and functional deficits in female mice, highlighting 12/15-LOX as a candidate target for female-predominant nociplastic pain.
Limits
This is an animal study without direct human data; clinical translation is unconfirmed. The abstract omits sample sizes, quantitative effect sizes, and statistical variance. The phenotype differed from previously published responses in C57BL/6J mice, indicating potential substrain-specific variability.
Cited by
- supports Lipopolysaccharides (LPS) drive pain through interactions with the central nervous system.